Skip to main
SUPN
SUPN logo

Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target

Supernus Pharmaceuticals (SUPN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 18%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

Supernus Pharmaceuticals Inc. is positioned positively due to its strong portfolio in the central nervous system therapeutics market, particularly highlighted by the anticipated growth of Qelbree, which is projected to achieve sales exceeding $600 million, bolstered by a new patent extension protecting it until 2035. The company benefits from a robust balance sheet that affords it the ability to pursue strategic acquisitions in the range of $500 million to $1.5 billion, potentially enhancing its market offerings. Furthermore, with a patient satisfaction rate of approximately 80% for Qelbree and a strong commercial presence, Supernus is well-positioned to leverage these factors for continued growth and expansion.

Bears say

Supernus Pharmaceuticals Inc has experienced a negative outlook due to the downgrade following disappointing Phase 2b data from its SPN-820 treatment for treatment-resistant depression. The company's potential market growth may be further diluted by commercial execution failures and the inherent risks associated with clinical trials, which could result in unfavorable outcomes. Additionally, the possibility of failing to secure regulatory approval for new or expanded indications may limit the adoption of Supernus' existing products among clinicians who may prefer established therapies.

Supernus Pharmaceuticals (SUPN) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 18% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Supernus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Supernus Pharmaceuticals (SUPN) Forecast

Analysts have given Supernus Pharmaceuticals (SUPN) a Buy based on their latest research and market trends.

According to 11 analysts, Supernus Pharmaceuticals (SUPN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Supernus Pharmaceuticals (SUPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.